Pavel Kubalec

Title: The Innovations of Pavel Kubalec

Introduction

Pavel Kubalec is a notable inventor based in Feldafing, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic monoclonal antibodies. With a total of 3 patents to his name, Kubalec's work has had a profound impact on medical research and treatment methodologies.

Latest Patents

Kubalec's latest patents include groundbreaking innovations. One of his patents is titled "Recombinant immunoglobulin heavy chains comprising a sortase conjugation loop and conjugates thereof." This patent describes a recombinant immunoglobulin heavy chain that includes a sortase conjugation loop, along with methods for conjugating and labeling these chains using the enzyme sortase. The resulting conjugates and labeled products obtained through this method are also detailed in the patent. Another significant patent is "Assay for measurement of antibodies binding to a therapeutic monoclonal antibody." This patent outlines methods and systems for determining the presence of anti-therapeutic monoclonal antibody antibodies in vitro from samples of patients treated with therapeutic monoclonal antibodies. It also includes methods for identifying patients at risk of developing adverse drug reactions during treatment.

Career Highlights

Throughout his career, Pavel Kubalec has worked with prominent companies in the biotechnology sector. He has been associated with Roche Diagnostics Operations, Inc. and F. Hoffmann-La Roche AG. His experience in these organizations has allowed him to contribute to various innovative projects and advancements in the field.

Collaborations

Kubalec has collaborated with several professionals in his field, including Ursula Klause and Barbara Upmeier. These collaborations have further enriched his research and development efforts.

Conclusion

Pavel Kubalec's contributions to biotechnology through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for advancements in therapeutic treatments and medical research.